Eli Lilly Japan holds annual earnings press conference, achieving record-high sales and the highest number of new drug development projects

Eli Lilly Japan held its annual press conference on May 11, 2026, announcing record-high sales of 276 billion yen for fiscal 2025, a 25% year-on-year increase. The company marked its third consecutive year of double-digit growth. President Simone Thomsen highlighted the company's commitment to patient value and announced that the number of domestic drug development projects is currently at an all-time high. The company is also enhancing its supply chain with a 20 billion yen investment in its Seishin plant and leveraging AI in research.